-
Je něco špatně v tomto záznamu ?
Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization
O. Vit, P. Talacko, Z. Musil, I. Hartmann, K. Pacak, J. Petrak
Status neindexováno Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
AZV NV19-01-00083, NU23-01-00323
Czech Agency for Healthcare Research
UNCE/MED/016 and Cooperatio program, research area BIOLOGY
Ministry of Education, Youth, and Sports of the Czech Republic (MSMT CR)
National Institute of Cancer Research - LX22NPO5102
European Union - Next Generation EU, Programme EXCELES
NLK
BioMedCentral
od 2004-03-01
BioMedCentral Open Access
od 2010
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2021-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2021-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2004
Springer Nature OA/Free Journals
od 2004-03-01
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. New drug targets and proteins that would assist sensitive PPGL imagining could improve therapy and quality of life of patients with PPGL, namely those with recurrent or metastatic disease. Using a combined proteomic strategy, we looked for such clinically relevant targets among integral membrane proteins (IMPs) upregulated on the surface of tumor cells and non-membrane druggable enzymes in PPGL. METHODS: We conducted a detailed proteomic analysis of 22 well-characterized human PPGL samples and normal chromaffin tissue from adrenal medulla. A standard quantitative proteomic analysis of tumor lysate, which provides information largely on non-membrane proteins, was accompanied by specific membrane proteome-aimed methods, namely glycopeptide enrichment using lectin-affinity, glycopeptide capture by hydrazide chemistry, and enrichment of membrane-embedded hydrophobic transmembrane segments. RESULTS: The study identified 67 cell surface integral membrane proteins strongly upregulated in PPGL compared to control chromaffin tissue. We prioritized the proteins based on their already documented direct role in cancer cell growth or progression. Increased expression of the seven most promising drug targets (CD146, CD171, ANO1, CD39, ATP8A1, ACE and SLC7A1) were confirmed using specific antibodies. Our experimental strategy also provided expression data for soluble proteins. Among the druggable non-membrane enzymes upregulated in PPGL, we identified three potential drug targets (SHMT2, ARG2 and autotaxin) and verified their upregulated expression. CONCLUSIONS: Application of a combined proteomic strategy recently presented as "Pitchfork" enabled quantitative analysis of both, membrane and non-membrane proteome, and resulted in identification of 10 potential drug targets in human PPGL. Seven membrane proteins localized on the cell surface and three non-membrane druggable enzymes proteins were identified and verified as significantly upregulated in PPGL. All the proteins have been previously shown to be upregulated in several human cancers, and play direct role in cancer progression. Marked upregulation of these proteins along with their localization and established direct roles in tumor progression make these molecules promising candidates as drug targets or proteins for sensitive PPGL imaging.
BIOCEV 1st Faculty of Medicine Charles University Vestec 25250 Czech Republic
Proteomics Core Facility Faculty of Science BIOCEV Charles University Vestec 25250 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23015234
- 003
- CZ-PrNML
- 005
- 20250109141521.0
- 007
- ta
- 008
- 231010s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12014-023-09428-7 $2 doi
- 035 __
- $a (PubMed)37749499
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vít, Ondřej $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, 25250, Czech Republic $7 xx0327709
- 245 10
- $a Identification of potential molecular targets for the treatment of cluster 1 human pheochromocytoma and paraganglioma via comprehensive proteomic characterization / $c O. Vit, P. Talacko, Z. Musil, I. Hartmann, K. Pacak, J. Petrak
- 520 9_
- $a BACKGROUND: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors. New drug targets and proteins that would assist sensitive PPGL imagining could improve therapy and quality of life of patients with PPGL, namely those with recurrent or metastatic disease. Using a combined proteomic strategy, we looked for such clinically relevant targets among integral membrane proteins (IMPs) upregulated on the surface of tumor cells and non-membrane druggable enzymes in PPGL. METHODS: We conducted a detailed proteomic analysis of 22 well-characterized human PPGL samples and normal chromaffin tissue from adrenal medulla. A standard quantitative proteomic analysis of tumor lysate, which provides information largely on non-membrane proteins, was accompanied by specific membrane proteome-aimed methods, namely glycopeptide enrichment using lectin-affinity, glycopeptide capture by hydrazide chemistry, and enrichment of membrane-embedded hydrophobic transmembrane segments. RESULTS: The study identified 67 cell surface integral membrane proteins strongly upregulated in PPGL compared to control chromaffin tissue. We prioritized the proteins based on their already documented direct role in cancer cell growth or progression. Increased expression of the seven most promising drug targets (CD146, CD171, ANO1, CD39, ATP8A1, ACE and SLC7A1) were confirmed using specific antibodies. Our experimental strategy also provided expression data for soluble proteins. Among the druggable non-membrane enzymes upregulated in PPGL, we identified three potential drug targets (SHMT2, ARG2 and autotaxin) and verified their upregulated expression. CONCLUSIONS: Application of a combined proteomic strategy recently presented as "Pitchfork" enabled quantitative analysis of both, membrane and non-membrane proteome, and resulted in identification of 10 potential drug targets in human PPGL. Seven membrane proteins localized on the cell surface and three non-membrane druggable enzymes proteins were identified and verified as significantly upregulated in PPGL. All the proteins have been previously shown to be upregulated in several human cancers, and play direct role in cancer progression. Marked upregulation of these proteins along with their localization and established direct roles in tumor progression make these molecules promising candidates as drug targets or proteins for sensitive PPGL imaging.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Talacko, Pavel $u Proteomics Core Facility, Faculty of Science, BIOCEV, Charles University, Vestec, 25250, Czech Republic
- 700 1_
- $a Musil, Zdenek $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital, Prague, 12800, Czech Republic
- 700 1_
- $a Hartmann, Igor $u Department of Urology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, 77900, Czech Republic
- 700 1_
- $a Pacak, Karel $u Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD, 20892, USA
- 700 1_
- $a Petrak, Jiri $u BIOCEV, First Faculty of Medicine, Charles University, Vestec, 25250, Czech Republic. jpetr@lf1.cuni.cz
- 773 0_
- $w MED00173375 $t Clinical proteomics $x 1542-6416 $g Roč. 20, č. 1 (2023), s. 39
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37749499 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231010 $b ABA008
- 991 __
- $a 20250109141515 $b ABA008
- 999 __
- $a ok $b bmc $g 1997058 $s 1201596
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 20 $c 1 $d 39 $e 20230925 $i 1542-6416 $m Clinical proteomics $n Clin Proteomics $x MED00173375
- GRA __
- $a AZV NV19-01-00083, NU23-01-00323 $p Czech Agency for Healthcare Research
- GRA __
- $a UNCE/MED/016 and Cooperatio program, research area BIOLOGY $p Ministry of Education, Youth, and Sports of the Czech Republic (MSMT CR)
- GRA __
- $a National Institute of Cancer Research - LX22NPO5102 $p European Union - Next Generation EU, Programme EXCELES
- LZP __
- $a Pubmed-20231010